Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models

Annals of Clinical and Translational Neurology

Volumn 2, Issue 10, 2015, Pages 978-983

  Kihara, Yasuyuki ^a   Groves, Aran ^a   Rivera, Richard R ^a   Chun, Jerold ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; B LYMPHOCYTE; BLOOD CELL COUNT; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84955460360     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.251     Document Type: Article

References (20)

1. Phillips JT, Fox RJ. BG-12 in multiple sclerosis. Semin Neurol 2013;33:56–65.
2. Rubant SA, Ludwig RJ, Diehl S, et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 2008;128:326–331.
3. Nieuwkamp DJ, Murk JL, van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015;372:1474–1476.
4. Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015;372:1476–1478.
5. Hauser SL, Weiner HL. Natalizumab: immune effects and implications for therapy. Ann Neurol 2006;59:731–732.
6. Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006;60:162–173.
7. Kihara Y, Matsushita T, Kita Y, et al. Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis. Proc Natl Acad Sci USA 2009;106:21807–21812.
8. Groves A, Kihara Y, Chun J. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013;328:9–18.
9. Turley AE, Zagorski JW, Rockwell CE. The Nrf2 activator tBHQ inhibits T cell activation of primary human CD4 T cells. Cytokine 2015;71:289–295.
10. Lehmann-Horn K, Sagan SA, Bernard CC, et al. B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity. Ann Neurol 2015;77:902–908.
11. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60:12–21.
12. Glatigny S, Duhen R, Arbelaez C, et al. Integrin alpha L controls the homing of regulatory T cells during CNS autoimmunity in the absence of integrin alpha 4. Sci Rep 2015;5:7834.
13. Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest 2014;124:2188–2192.
14. Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. J Neurol 2013;260:2297–2305.
15. Hutchinson M, Fox RJ, Miller DH, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol 2013;260:2286–2296.
16. Crooks CV, Cross ML, Wall CR. Age-related differences in integrin expression in peripheral blood lymphocytes. Immun Ageing 2010;7:5.
17. Soilu-Hanninen M, Laaksonen M, Hanninen A, et al. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. J Neuroimmunol 2005. 167:175–182.
18. Theien BE, Vanderlugt CL, Eagar TN, et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2001;107:995–1006.
19. Lehmann HC, Kruger K, Fink GR, Schroeter M. Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy. J Neurol 2015;262:771–773.
20. Baron JL, Madri JA, Ruddle NH, et al. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993;177:57–68.